**Supplementary Table S3**

Supplementary Table S5: Comparison of PBMC subsets (major subsets, CD4 subsets, CD8 subsets, Tregs, and T-cell activation status) and plasma immune response and checkpoint markers in the whole patient population between baseline and after three months of combination therapy. The number of measurements (N), median, interquartile range (IQR), raw p-values, and FDR-corrected p-values are reported. The P-values were calculated using a paired Wilcoxon signed rank test. The p-values below the significance threshold of 5% are indicated in bold italics. FDR: false discovery rate; MFI: mean fluorescence intensity.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Biomarker** | **Baseline** | | **After 3 months** | | ***P*-values** | |
| **N** | **Median [IQR]** | **N** | **Median [IQR]** | **Raw** | **FDR** |
| **PBMC - Major Subsets** |  |  |  |  |  |  |
| Viable cells (% of total cells) | 20 | 98.99 [98.29;99.26] | 20 | 99.19 [98.76;99.61] | 0.182 | 0.327 |
| Viable lymphocytes (% of total lymphocytes) | 20 | 97.36 [93.46;98.17] | 20 | 97.92 [96.94;98.59] | ***0.019*** | 0.087 |
| Total T-cells (% of viable lymphocytes) | 20 | 62.16 [55.47;68.32] | 20 | 61.97 [52.98;69.93] | 0.841 | 0.946 |
| Total T-cells (% of viable cells) | 20 | 57.50 [45.84;62.30] | 20 | 57.07 [46.77;64.40] | 1.000 | 1.000 |
| CD4+ T-cells (% of viable lymphocytes) | 20 | 51.66 [39.48;56.80] | 20 | 51.17 [41.65;56.88] | 0.841 | 0.946 |
| CD8+ T-cells (% of viable lymphocytes) | 20 | 15.91 [11.36;18.93] | 20 | 12.58 [9.09;18.00] | 0.123 | 0.327 |
| CD4/CD8 ratio (% CD4/CD8 ratio) | 20 | 3.58 [2.42;4.65] | 20 | 3.31 [2.62;6.73] | 0.202 | 0.331 |
| NK/T-cells (% of viable cells) | 20 | 2.61 [1.49;5.78] | 20 | 3.70 [1.78;5.62] | 0.898 | 0.951 |
| Total NK cells (% of viable cells) | 20 | 7.86 [3.69;11.22] | 20 | 9.63 [6.76;13.51] | 0.154 | 0.327 |
| CD56 bright CD16- (% of total NK cells) | 20 | 4.66 [3.22;9.34] | 20 | 5.90 [3.54;12.09] | 0.414 | 0.622 |
| CD56 dim CD16+ (% of total NK cells) | 20 | 68.35 [47.60;82.71] | 20 | 64.98 [50.43;88.52] | 0.571 | 0.790 |
| Total B-cells (% of viable cells) | 20 | 8.65 [6.16;9.83] | 20 | 8.28 [5.35;11.73] | 0.622 | 0.799 |
| Naive B-cells (% of total B-cells) | 20 | 60.80 [50.18;74.87] | 20 | 74.80 [63.53;80.94] | ***0.001*** | ***0.012*** |
| Memory B-cells (% of total B-cells) | 20 | 37.94 [24.10;47.79] | 20 | 24.48 [18.23;35.21] | ***0.001*** | ***0.012*** |
| Total monocytes (% of viable cells) | 20 | 14.81 [10.16;23.10] | 20 | 14.40 [7.36;19.17] | 0.177 | 0.327 |
| Non-classical monocytes (% of total monocytes) | 20 | 4.23 [1.98;6.55] | 20 | 6.16 [3.42;11.02] | 0.154 | 0.327 |
| Intermediate monocytes (% of total monocytes) | 20 | 6.17 [4.46;7.04] | 20 | 8.41 [6.23;11.84] | ***0.002*** | ***0.012*** |
| Classical monocytes (% of total monocytes) | 20 | 80.89 [72.55;85.10] | 20 | 73.97 [63.39;81.42] | ***0.044*** | 0.159 |
| **PBMC - CD4 Subsets** |  |  |  |  |  |  |
| Naïve CD4+ (% of CD4+ T-cells) | 20 | 42.15 [19.56;50.27] | 20 | 45.14 [24.22;58.97] | ***0.012*** | ***0.023*** |
| CD27 expression in Naïve CD4+ (MFI) | 20 | 1334.50 [1162.00;1668.50] | 20 | 1733.00 [1476.50;2001.00] | ***0.002*** | ***0.005*** |
| CD28 expression in Naïve CD4+ (MFI) | 20 | 686.50 [569.00;825.00] | 20 | 806.00 [712.00;844.50] | ***0.015*** | ***0.025*** |
| Naïve CD4+ CD27+ CD28+ (% of Naïve CD4+ T-cells) | 20 | 91.71 [87.13;94.63] | 20 | 96.29 [94.83;98.49] | ***<0.001*** | ***0.005*** |
| CD27 expression in Naïve CD4+ CD27+CD28+ (MFI) | 20 | 1424.50 [1265.00;1765.50] | 20 | 1770.50 [1552.00;2023.50] | ***0.005*** | ***0.010*** |
| CD28 expression in Naïve CD4+ CD27+CD28+ (MFI) | 20 | 696.50 [590.00;829.00] | 20 | 803.00 [717.50;841.50] | ***0.023*** | ***0.032*** |
| Naïve CD4+ CD57+ (% of Naïve CD4+ T-cells) | 20 | 4.07 [1.48;11.63] | 20 | 3.06 [0.78;8.97] | 0.504 | 0.554 |
| CM CD4+ (% of CD4+ T-cells) | 20 | 53.77 [37.11;62.96] | 20 | 46.21 [29.38;58.71] | ***0.017*** | ***0.026*** |
| CD27 expression in CM CD4+ (MFI) | 19 | 1170.00 [885.00;1436.00] | 19 | 1477.00 [1216.00;1758.00] | ***0.001*** | ***0.005*** |
| CD28 expression in CM CD4+ (MFI) | 20 | 1180.00 [936.00;1290.50] | 20 | 1224.00 [1098.50;1358.00] | ***0.019*** | ***0.028*** |
| CM CD4+ CD27+ CD28+ (% of CM CD4+ T-cells) | 20 | 76.72 [65.75;82.10] | 20 | 85.23 [77.53;88.89] | ***<0.001*** | ***0.004*** |
| CD27 expression in CM CD4+ CD27+CD28+ (MFI) | 20 | 1386.50 [1222.00;1711.50] | 20 | 1647.00 [1483.00;1917.00] | ***0.001*** | ***0.005*** |
| CD28 expression in CM CD4+ CD27+CD28+ (MFI) | 20 | 1185.50 [961.50;1263.50] | 20 | 1211.00 [1103.00;1335.50] | ***0.014*** | ***0.024*** |
| CM CD4+ CD57+ (% of CM CD4+ T-cells) | 20 | 2.47 [1.61;3.44] | 20 | 1.95 [1.53;3.06] | 0.335 | 0.394 |
| EM CD4+ (% of CD4+ T-cells) | 20 | 10.51 [6.70;15.07] | 20 | 9.15 [5.77;13.73] | 0.231 | 0.293 |
| CD27 expression in EM CD4+ (MFI) | 19 | 380.00 [280.00;522.00] | 19 | 502.00 [368.00;793.00] | ***0.001*** | ***0.005*** |
| CD28 expression in EM CD4+ (MFI) | 20 | 964.00 [834.50;1242.50] | 20 | 1131.00 [1023.00;1260.00] | ***0.012*** | ***0.023*** |
| EM CD4+ CD27+ CD28+(% of EM CD4+ T-cells) | 20 | 31.26 [21.65;41.04] | 20 | 39.21 [32.27;52.50] | ***0.001*** | ***0.005*** |
| CD27 expression in EM CD4+ CD27+CD28+ (MFI) | 20 | 1146.00 [995.50;1310.00] | 20 | 1336.50 [1252.00;1563.50] | ***0.001*** | ***0.005*** |
| CD28 expression in EM CD4+ CD27+CD28+ (MFI) | 20 | 1099.50 [960.00;1286.50] | 20 | 1209.00 [1148.00;1374.50] | ***0.002*** | ***0.007*** |
| EM CD4+ CD27+CD28- (% of EM CD4+ T-cells) | 20 | 0.13 [0.00;0.40] | 20 | 0.11 [0.04;0.27] | 0.106 | 0.140 |
| EM CD4+ CD27-CD28- (% of EM CD4+ T-cells) | 20 | 2.43 [1.23;8.52] | 20 | 1.79 [0.69;5.37] | 0.522 | 0.555 |
| EM CD4+ CD27-CD28+ (% of EM CD4+ T-cells) | 20 | 58.93 [53.20;67.31] | 20 | 48.15 [44.20;64.09] | ***0.003*** | ***0.007*** |
| EM CD4+ CD57+ (% of EM CD4+ T-cells) | 20 | 1.88 [1.13;8.33] | 20 | 1.87 [1.20;4.17] | 0.312 | 0.381 |
| TEMRA CD4+(% of CD4+ T-cells) | 20 | 0.48 [0.27;1.92] | 20 | 0.49 [0.26;1.63] | 0.735 | 0.758 |
| CD27 expression in TEMRA CD4+ (MFI) | 17 | 398.00 [154.00;545.00] | 17 | 632.00 [346.00;891.00] | ***0.003*** | ***0.008*** |
| CD28 expression in TEMRA CD4+ (MFI) | 20 | 692.50 [231.50;943.50] | 20 | 963.00 [506.50;1171.00] | ***0.012*** | ***0.023*** |
| TEMRA CD4+ CD27+CD28+ (% of TERMA CD4+ T-cells) | 20 | 26.93 [11.58;42.57] | 20 | 32.74 [20.24;53.91] | ***0.002*** | ***0.005*** |
| CD27 expression in TEMRA CD4+ CD27+CD28+ (MFI) | 20 | 1092.50 [937.00;1301.50] | 20 | 1493.00 [1172.00;1639.50] | ***0.001*** | ***0.005*** |
| CD28 expression in TEMRA CD4+ CD27+CD28+ (MFI) | 20 | 1061.00 [887.00;1173.00] | 20 | 1245.00 [975.00;1525.50] | ***0.001*** | ***0.005*** |
| TEMRA CD4+ CD27+CD28- (% of TEMRA CD4+ T-cells) | 20 | 1.63 [0.00;10.42] | 20 | 3.00 [0.07;5.95] | 0.782 | 0.782 |
| TEMRA CD4+ CD27-CD28- (% of TEMRA CD4+ T-cells) | 20 | 18.64 [8.39;38.84] | 20 | 10.10 [3.57;31.62] | ***0.016*** | ***0.025*** |
| TEMRA CD4+ CD57+ (% of TEMRA CD4+ T-cells) | 20 | 34.32 [17.33;67.51] | 20 | 28.59 [10.78;61.93] | 0.368 | 0.419 |
| **PBMC - CD8 Subsets** |  |  |  |  |  |  |
| Naïve CD8+ (% of CD8+ T-cells) | 20 | 17.62 [8.89;44.02] | 20 | 21.62 [14.09;41.89] | ***0.036*** | 0.085 |
| CD27 expression in Naïve CD8+ (MFI) | 20 | 1396.00 [1188.00;1865.00] | 20 | 1921.00 [1434.50;2255.00] | ***0.006*** | ***0.023*** |
| CD28 expression in Naïve CD8+ (MFI) | 20 | 577.50 [466.00;662.00] | 20 | 584.00 [510.00;663.00] | 0.257 | 0.339 |
| Naïve CD8+ CD27+ CD28+ (% of Naïve CD8+ T-cells) | 20 | 72.14 [60.73;86.15] | 20 | 88.64 [73.50;94.74] | ***0.006*** | ***0.023*** |
| CD27 expression in Naïve CD8+ CD27+CD28+ (MFI) | 20 | 1683.50 [1548.50;2036.00] | 20 | 2057.00 [1755.50;2437.00] | ***0.002*** | ***0.019*** |
| CD28 expression in Naïve CD8+ CD27+CD28+ (MFI) | 20 | 605.50 [517.50;691.50] | 20 | 610.50 [538.00;674.50] | 0.231 | 0.331 |
| Naïve CD8+ CD57+ (% of Naïve CD8+ T-cells) | 20 | 4.13 [2.10;7.11] | 20 | 2.40 [1.40;4.15] | 0.316 | 0.373 |
| CM CD8+ (% of CD8+ T-cells) | 20 | 25.91 [17.36;33.04] | 20 | 18.02 [15.82;28.72] | 0.105 | 0.166 |
| CD27 expression in CM CD8+ (MFI) | 20 | 1059.00 [800.50;1284.00] | 20 | 1313.00 [955.00;1638.00] | ***0.002*** | ***0.019*** |
| CD28 expression in CM CD8+ (MFI) | 20 | 939.50 [769.50;1038.00] | 20 | 947.00 [809.00;1111.00] | ***0.040*** | 0.088 |
| CM CD8+ CD27+ CD28+ (% of CM CD8+ T-cells) | 20 | 66.45 [51.44;73.09] | 20 | 75.44 [61.14;85.70] | ***0.011*** | ***0.035*** |
| CD27 expression in CM CD8+ CD27+CD28+ (MFI) | 20 | 1416.50 [1221.00;1582.00] | 20 | 1605.00 [1383.00;1874.50] | ***0.002*** | ***0.019*** |
| CD28 expression in CM CD8+ CD27+CD28+ (MFI) | 20 | 1006.00 [847.00;1079.50] | 20 | 993.00 [882.00;1127.00] | 0.058 | 0.113 |
| CM CD8+ CD57+ (% of CM CD8+ T-cells) | 20 | 10.78 [6.78;13.82] | 20 | 10.64 [7.35;14.80] | 0.701 | 0.746 |
| EM CD8+ (% of CD8+ T-cells) | 20 | 25.14 [14.66;34.27] | 20 | 26.06 [12.65;33.73] | 0.083 | 0.136 |
| CD27 expression in EM CD8+ (MFI) | 20 | 498.50 [390.50;658.00] | 20 | 690.00 [485.00;877.50] | ***0.003*** | ***0.020*** |
| CD28 expression in EM CD8+ (MFI) | 20 | 482.00 [372.00;605.50] | 20 | 583.00 [354.00;703.00] | 0.071 | 0.127 |
| EM CD8+ CD27+ CD28+(% of EM CD8+ T-cells) | 20 | 17.57 [11.12;27.87] | 20 | 29.98 [15.76;37.23] | ***0.006*** | ***0.023*** |
| CD27 expression in EM CD8+ CD27+CD28+ (MFI) | 20 | 1329.00 [1241.50;1434.50] | 20 | 1385.00 [1297.50;1636.50] | ***0.012*** | ***0.036*** |
| CD28 expression in EM CD8+ CD27+CD28+ (MFI) | 20 | 802.00 [752.50;919.00] | 20 | 859.00 [679.00;1014.50] | 0.273 | 0.347 |
| EM CD8+ CD27+CD28- (% of EM CD8+ T-cells) | 20 | 3.01 [1.44;5.60] | 20 | 3.48 [1.85;6.10] | 0.058 | 0.113 |
| EM CD8+ CD27-CD28- (% of EM CD8+ T-cells) | 20 | 25.63 [18.46;40.40] | 20 | 24.14 [15.89;38.55] | 0.312 | 0.373 |
| EM CD8+ CD27-CD28+ (% of EM CD8+ T-cells) | 20 | 46.55 [35.80;59.77] | 20 | 37.81 [28.56;49.84] | ***0.004*** | ***0.020*** |
| EM CD8+ CD57+ (% of EM CD8+ T-cells) | 20 | 44.77 [28.23;57.00] | 20 | 48.30 [31.43;54.52] | 0.956 | 0.956 |
| TEMRA CD8+(% of CD8+ T-cells) | 20 | 23.61 [11.02;33.31] | 20 | 24.01 [10.82;31.82] | 0.898 | 0.926 |
| CD27 expression in TEMRA CD8+ (MFI) | 20 | 266.50 [205.00;438.50] | 20 | 291.50 [218.50;578.50] | ***0.021*** | 0.058 |
| CD28 expression in TEMRA CD8+ (MFI) | 20 | 141.50 [76.00;225.50] | 20 | 141.00 [81.00;228.50] | 0.430 | 0.490 |
| TEMRA CD8+ CD27+CD28+ (% of TERMA CD8+ T-cells) | 20 | 4.02 [1.95;5.575] | 20 | 4.36 [2.34;10.53] | ***0.033*** | 0.083 |
| CD27 expression in TEMRA CD8+ CD27+CD28+ (MFI) | 19 | 1515.00 [1345.00;1642.00] | 19 | 1638.00 [1455.00;1767.00] | 0.073 | 0.127 |
| CD28 expression in TEMRA CD8+ CD27+CD28+ (MFI) | 19 | 703.00 [653.00;791.00] | 19 | 761.00 [633.00;827.00] | 0.214 | 0.321 |
| TEMRA CD8+ CD27+CD28- (% of TEMRA CD8+ T-cells) | 20 | 1.54 [0.52;2.82] | 20 | 3.71 [1.35;5.48] | ***0.001*** | ***0.019*** |
| TEMRA CD8+ CD27-CD28- (% of TEMRA CD8+ T-cells) | 20 | 73.78 [59.53;84.14] | 20 | 71.32 [57.63;84.78] | 0.452 | 0.498 |
| TEMRA CD8+ CD57+ (% of TEMRA CD8+ T-cells) | 20 | 64.46 [56.19;77.01] | 20 | 69.87 [59.59;79.18] | 0.246 | 0.338 |
| **PBMC - Tregs** |  |  |  |  |  |  |
| Total Treg (% of CD4+ T-cells) | 20 | 5.03 [3.88;6.89] | 20 | 4.59 [3.34;5.36] | 0.165 | 0.259 |
| CD25 expression in Total Treg (MFI) | 20 | 1606.00 [1185.00;2203.50] | 20 | 2077.00 [1235.50;2947.50] | ***0.033*** | 0.072 |
| CTLA-4 expression in Total Treg (MFI) | 20 | 250.50 [228.50;296.50] | 20 | 284.00 [237.00;316.00] | 0.153 | 0.259 |
| Naïve Treg (% of total Tregs) | 20 | 5.94 [3.67;9.51] | 20 | 10.41 [5.20;17.12] | ***<0.001*** | ***0.001*** |
| CD25 expression of Naïve Treg (MFI) | 20 | 1447.50 [835.00;1940.50] | 20 | 2021.00 [1382.50;2454.50] | ***0.011*** | ***0.039*** |
| CTLA-4 expression of Naïve Treg (MFI) | 20 | 229.00 [186.00;284.00] | 20 | 268.50 [204.50;310.50] | 0.245 | 0.337 |
| Naïve Treg CTLA-4+ (% of Naïve Tregs) | 20 | 23.25 [15.94;36.73] | 20 | 27.44 [17.37;32.09] | 0.953 | 0.953 |
| Memory Treg (% of total Tregs) | 20 | 93.77 [89.80;96.00] | 20 | 88.90 [82.46;93.80] | ***<0.001*** | ***0.001*** |
| CD25 expression of Memory Treg (MFI) | 20 | 1633.00 [1186.00;2178.00] | 20 | 2057.00 [1255.50;2984.00] | ***0.024*** | 0.066 |
| CTLA-4 expression of Memory Treg (MFI) | 20 | 255.00 [230.50;296.00] | 20 | 273.00 [233.50;313.50] | 0.316 | 0.384 |
| Memory Treg CTLA-4+ (% of Memory Tregs) | 20 | 18.10 [15.59;20.69] | 20 | 18.50 [14.28;24.46] | 0.349 | 0.384 |
| **PBMC – T-cell activation status** |  |  |  |  |  |  |
| CD4+ PD1+ (% of CD4+ T-cells) | 20 | 1.55 [0.89;2.14] | 20 | 1.32 [0.92;3.03] | 0.738 | 0.876 |
| PD1 expression in CD4+ (MFI) | 20 | 201.50 [127.50;235.00] | 20 | 196.00 [145.00;236.00] | 0.335 | 0.669 |
| CD4+ CD69+ (% of CD4+ T-cells) | 20 | 31.94 [22.42;40.79] | 20 | 28.54 [21.94;40.29] | 0.546 | 0.819 |
| CD69 expression in CD4+ (MFI) | 20 | 253.50 [235.00;270.00] | 20 | 254.50 [229.00;297.50] | 0.373 | 0.689 |
| CD4+ PD1+CD69+ (% of CD4+ T-cells) | 20 | 0.93 [0.64;1.58] | 20 | 0.90 [0.58;1.80] | 0.985 | 0.985 |
| CD4+ PD1-CD69- (% of CD4+ T-cells) | 20 | 67.43 [58.65;76.96] | 20 | 70.80 [58.65;77.06] | 0.729 | 0.876 |
| CD4+ HLADR+ (% of CD4+ T-cells) | 20 | 14.41 [7.91;19.78] | 20 | 15.46 [10.39;22.02] | 0.114 | 0.455 |
| HLADR expression in CD4+ (MFI) | 20 | 401.00 [332.50;552.50] | 20 | 421.50 [348.00;506.50] | 0.674 | 0.876 |
| CD4+ CD38+ (% of CD4+ T-cells) | 20 | 31.90 [20.25;45.58] | 20 | 34.62 [22.85;44.25] | 0.177 | 0.472 |
| CD38 expression in CD4+ (MFI) | 20 | 653.50 [488.50;777.00] | 20 | 655.00 [504.00;780.00] | 0.877 | 0.957 |
| CD4+ HLADR+CD38+ (% of CD4+ T-cells) | 20 | 3.08 [1.80;4.02] | 20 | 3.99 [1.94;5.94] | 0.066 | 0.364 |
| CD4+ HLADR-CD38- (% of CD4+ T-cells) | 20 | 54.84 [48.00;67.32] | 20 | 54.62 [41.38;59.53] | 0.133 | 0.455 |
| CD8+ PD1+ (% of CD8+ T-cells) | 20 | 21.31 [12.77;29.14] | 20 | 23.81 [11.97;36.39] | 0.430 | 0.738 |
| PD1 expression in CD8+ (MFI) | 20 | 270.50 [223.00;357.00] | 20 | 292.50 [222.50;380.00] | 0.766 | 0.876 |
| CD8+ CD69+ (% of CD8+ T-cells) | 20 | 31.63 [21.01;47.02] | 20 | 37.83 [19.23;45.60] | 0.701 | 0.876 |
| CD69 expression in CD8+ (MFI) | 20 | 390.50 [319.00;522.50] | 20 | 470.50 [371.00;645.50] | 0.154 | 0.461 |
| CD8+ PD1+CD69+ (% of CD8+ T-cells) | 20 | 7.85 [5.28;12.60] | 20 | 8.60 [4.92;18.08] | 0.294 | 0.642 |
| CD8+ PD1-CD69- (% of CD8+ T-cells) | 20 | 50.24 [39.40;65.04] | 20 | 49.07 [39.66;62.29] | 0.927 | 0.968 |
| CD8+ HLADR+ (% of CD8+ T-cells) | 20 | 40.22 [26.35;46.38] | 20 | 41.86 [32.36;51.53] | 0.076 | 0.364 |
| HLADR expression in CD8+ (MFI) | 20 | 505.50 [449.00;615.50] | 20 | 513.00 [405.00;629.00] | 0.515 | 0.819 |
| CD8+ CD38+ (% of CD8+ T-cells) | 20 | 11.97 [6.20;18.90] | 20 | 12.11 [7.00;24.92] | ***0.007*** | 0.172 |
| CD38 expression in CD8+ (MFI) | 20 | 280.00 [203.00;350.00] | 20 | 274.50 [201.00;435.50] | 0.273 | 0.642 |
| CD8+ HLADR+CD38+ (% of CD8+ T-cells) | 20 | 5.13 [3.40;9.04] | 20 | 6.51 [3.86;11.61] | 0.064 | 0.364 |
| CD8+ HLADR-CD38- (% of CD8+ T-cells) | 20 | 53.63 [48.44;58.46] | 20 | 48.05 [41.17;57.65] | ***0.036*** | 0.364 |
| **Plasma - Essential Immune Response** |  |  |  |  |  |  |
| IL-4 (pg/mL) | 20 | 0.06 [0.00;4.26] | 20 | 0.33 [0.00;9.84] | 0.890 | 0.898 |
| IL-2 (pg/mL) | 20 | 2.06 [0.96;4.02] | 20 | 1.44 [0.08;6.75] | 0.898 | 0.898 |
| CXCL-10 (IP-10) (pg/mL) | 20 | 218.23 [157.45;354.14] | 20 | 391.26 [166.73;459.55] | ***0.036*** | 0.217 |
| IL-1 beta (pg/mL) | 20 | 5.27 [0.77;14.48] | 20 | 4.57 [1.16;13.83] | 0.862 | 0.898 |
| TNF alpha (pg/mL) | 20 | 2.02 [1.53;3.43] | 20 | 1.92 [0.86;3.38] | 0.294 | 0.589 |
| CCL2 (MCP-1) (pg/mL) | 20 | 153.92 [115.28;207.57] | 20 | 185.79 [148.30;248.67] | 0.133 | 0.531 |
| IL-17A (pg/mL) | 20 | 2.55 [1.23;8.50] | 20 | 2.33 [1.36;6.85] | 0.196 | 0.587 |
| IL-6 (pg/mL) | 20 | 6.46 [2.88;9.01] | 20 | 5.88 [2.73;10.83] | 0.261 | 0.589 |
| IL-10 (pg/mL) | 20 | 1.85 [0.67;3.12] | 20 | 0.61 [0.02;1.68] | ***0.009*** | 0.101 |
| IFN gamma (pg/mL) | 20 | 1.29 [0.00;6.07] | 20 | 2.33 [1.30;6.23] | 0.799 | 0.898 |
| IL-12p70 (pg/mL) | 20 | 4.05 [1.81;6.93] | 20 | 3.67 [2.08;12.22] | 0.596 | 0.898 |
| CXCL-8 (IL-8) (pg/mL) | 20 | 4.30 [2.49;11.62] | 20 | 5.47 [3.20;14.38] | 0.648 | 0.898 |
| **Plasma - Immune Checkpoint** |  |  |  |  |  |  |
| sCD25 (IL-2Ra) (pg/mL) | 20 | 1139.20 [837.97;1965.60] | 20 | 1449.60 [994.13;2002.60] | ***0.024*** | 0.096 |
| 4-1BB (pg/mL) | 20 | 70.44 [54.40;156.36] | 20 | 59.59 [43.26;128.39] | ***0.048*** | 0.097 |
| sCD27 (pg/mL) | 20 | 55467.00 [48711.00;81131.00] | 20 | 54618.00 [49390.00;71250.00] | ***0.048*** | 0.097 |
| B7.2 (CD86) (pg/mL) | 20 | 543.30 [463.44;697.47] | 20 | 368.31 [314.93;584.11] | ***0.001*** | ***0.017*** |
| Free Active TGF-B1 (pg/mL) | 20 | 25.01 [18.60;35.43] | 20 | 21.13 [8.38;35.87] | 0.083 | 0.142 |
| CTLA-4 (pg/mL) | 20 | 8.84 [2.71;17.19] | 20 | 7.90 [2.69;14.50] | ***0.032*** | 0.097 |
| PD-L1 (pg/mL) | 20 | 200.04 [118.47;306.25] | 20 | 195.22 [149.03;303.77] | 0.956 | 0.956 |
| PD-L2 (pg/mL) | 20 | 12681.00 [10866.00;15195.00] | 20 | 14435.00 [11462.00;16359.00] | 0.123 | 0.185 |
| PD-1 (pg/mL) | 20 | 49.94 [16.51;151.25] | 20 | 27.45 [16.80;98.56] | ***0.005*** | ***0.029*** |
| Tim-3 (pg/mL) | 20 | 22351.00 [13890.00;33622.00] | 20 | 19419.00 [14642.00;33057.00] | 0.898 | 0.956 |
| LAG-3 (pg/mL) | 20 | 2905.30 [1775.20;7456.10] | 20 | 2098.10 [1575.00;6071.20] | 0.596 | 0.715 |
| Gal-9 (pg/mL) | 20 | 105359.00 [83066.00;150470.00] | 20 | 118096.00 [93697.00;167533.00] | 0.165 | 0.220 |